Aug 25, 2010
By:
George Koroneos
Results from a new study reveal that patients taking Takeda's diabetes treatment Actos have the same rate and kind of side effects as GSK's embattled Avandia. Is this a good sign?
|
Aug 18, 2010
By:
George Koroneos
In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.
|
Aug 11, 2010
By:
George Koroneos
Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.
|
Aug 4, 2010
By:
George Koroneos
In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.
|
Aug 2, 2010
By:
George Koroneos
Former Idun Pharma team buys back company from Pfizer.
|
|
Aug 1, 2010
By:
George Koroneos
Pharma's quest for patient adherence has been trying. Could better patient education be the answer?
|
Jul 20, 2010
By:
George Koroneos
Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.
|
Jun 30, 2010
By:
George Koroneos
FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.
|
Jun 30, 2010
By:
George Koroneos
GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
